Jan 06, 2022 / 07:00PM GMT
Nathan Allen Rich - Goldman Sachs Group, Inc., Research Division - Research Analyst
Good afternoon, everyone, and thank you for joining for our next session. My name is Nathan Rich, and I cover the dental space here at Goldman Sachs. We're very pleased to welcome Envista, the second largest dental manufacturer globally to our CEOs unscripted conference today. We're joined by the company's CEO, Amir Aghdaei.
Amir, thank you so much for joining us. We really appreciate your time this afternoon. Before we get started, I'd just like to remind the audience that if you would like to submit a question, you can do so through the webcast or by e-mailing me at [email protected].
Questions and Answers:
Nathan Allen Rich - Goldman Sachs Group, Inc., Research Division - Research AnalystAmir, definitely a busy end of the year for the company with the acquisition of Carestream's intra-oral scanner business. You finally got the FDA approval of the N1 implant system, completed the KaVo divestiture early in the year here. Maybe to start with the Carestream deal,
Trustpilot
